Company
Trethera
Privately held, clinical-stage biopharmaceutical company in Sherman Oaks, California, incorporated in 2013 as Triangle Therapeutics and built on UCLA research into deoxycytidine kinase. Its lead candidate, TRE-515, is a first-in-class oral dCK inhibitor now in Phase 1 testing across cancer and autoimmune disease.
1 story
Regulatory News has published 1 story about Trethera on 6 October 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 6 October 2026.
This page is generated from Regulatory News’ editorial coverage of Trethera. It is not an advertisement.
On the record
- Company
- Trethera Corporation
- Headquarters
- Sherman Oaks, California
- Founded
- 2013, as Triangle Therapeutics; a UCLA spinoff built on dCK research from Caius Radu, Johannes Czernin, Mike Jung and Owen Witte
- Regulator
- U.S. Food and Drug Administration (FDA)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
